An observational study in Joint Diseases, sponsored by MicroPort Orthopedics Inc.. Recruiting at 1 site in Italy. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2024-01-22.
Sponsored by MicroPort Orthopedics Inc. (part of MicroPort Scientific Corporation) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Joint Diseases by MicroPort Scientific Corporation — 5 open to participants now, 13 under way, none of them phase 3. Joint Diseases · MicroPort Scientific Corporation.
Among the 21 studies in Joint Diseases by MicroPort Scientific Corporation, this one is the 15th largest by planned enrollment of the 20 observational ones that give a count, is the only one that started in 2023, is one of 20 observational ones, reaches primary completion later than 12 of the 12 other live ones, and was the 20th registered.
386 studies on the registry are indexed under Joint Diseases; 64 are open to participants now.
Browse Joint Diseases studies →5 of the 21 studies in Joint Diseases by MicroPort Scientific Corporation are open now, in 5 countries. Recruiting first, the newest first:
MicroPort Orthopedics Inc. · Sites in United States, United Kingdom
Ages 21+
MicroPort Orthopedics Inc. · Sites in United States
Ages 21+
MicroPort Orthopedics Inc. · Sites in Poland
MicroPort Orthopedics Inc. · Sites in Germany
Ages 21+
By country, each count listing its studies:
Of the 44 Joint Diseases studies recruiting now, 24 (55%) set no upper age limit and 11 (25%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 45 is below the median of 86 across 116 observational studies indexed under Joint Diseases.
Median enrollment 0 across the 1 interventional studies, 69 across the 20 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under MicroPort Orthopedics Inc., one of the names counted as MicroPort Scientific Corporation. Under that name alone:
MicroPort Orthopedics Inc. is the lead sponsor of 26 studies on the registry; 6 are open to participants now.
3 of the studies in Joint Diseases by MicroPort Scientific Corporation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02351414MicroPort Orthopedics Inc.Post Market Follow-Up Study of the EVOLUTION® Total Knee Arthroplasty System With Cruciate Sacrificing Inserts | 2027-06 |
| NCT02823834MicroPort Orthopedics Inc.PMCF Study Protocol for PROFEMUR® Gladiator Plasma Femoral Stems and PROCOTYL® L Beaded Acetabular Components | 2027-06 |
| NCT02239783MicroPort Orthopedics Inc.Post Market Clinical Follow-Up Study Protocol for PROFEMUR® TL Modular Femoral Stems | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies in Joint Diseases by MicroPort Scientific Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
MicroPort (MPO) is conducting this PMCF study to evaluate the safety and effectiveness of its EVOLUTION® Revision Tibial System and EVOLUTION® Revision STEMMED CS Femur with the EVOLUTION® MP CS Tibial Insert. This type of study is required by regulatory authorities for all devices that have been approved in Europe to evaluate the medium and long-term clinical evidence.
The primary objective of this study is to estimate individual component survivorship for tibial base, femoral component, and tibial insert at specified intervals out to 10 years follow-up.
The secondary objectives include:
Multicenter, prospective follow-up study of newly or previously implanted subjects. Previously implanted subjects must be enrolled within 3 years (+ 6 months) of the study index surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single study group with either newly or previously implanted subjects with the EVOLUTION® Revision Tibia and EVOLUTION® Revision STEMMED CS Femur with the EVOLUTION® MP CS Insert.
Device: EVOLUTION® Revision Tibial System and EVOLUTION® Stemmed CS Femur with the EVOLUTION® MP CS Tibial Insert
Primary knee arthroplasty or a revision knee that requires a revision procedure.
The proportion of EVOLUTION® Revision Tibial Base components survivorship out to 10 years.
Percentage of knees survived with no revision or replacement at 10-year
Time frame: up to 10 years
The proportion of EVOLUTION® STEMMED CS Femoral components survivorship out to 10 years.
Percentage of knees survived with no revision or replacement at 10-year
Time frame: up to 10 years
The proportion of EVOLUTION® MP CS tibial inserts survivorship out to 10 years.
Percentage of knees survived with no revision or replacement at 10-year
Time frame: up to 10 years
Functional Scores
To assess functional scores utilizing Knee Injury and Osteoarthritis Outcome Score (KOOS Scores) out to 10 years follow-up.
Time frame: Year 1,Year 3, Year 5, Year 7, and Year 10
Functional Scores
To assess subject satisfaction with their Total Knee Arthroplasty (TKA) procedure utilizing the Forgotten Joint Score (FJS) at specified intervals out to 10 years follow-up.
Time frame: Year 1,Year 3, Year 5, Year 7, and Year 10
Functional Scores
To assess functional scores utilizing EQ-5D-5L at specified intervals out to 10 years follow-up.
Time frame: Year 1,Year 3, Year 5, Year 7, and Year 10
Subject Satisfaction
To assess subject satisfaction with their TKA procedure via the Satisfaction Survey at specified intervals out to 10 years follow-up.
Time frame: Year 1,Year 3, Year 5, Year 7, and Year 10
Radiolucencies
To assess the presence of radiolucencies surrounding the implanted components at specified intervals out to 10 years follow-up.
Time frame: Year 1,Year 3, Year 5, Year 7, and Year 10
To assess subject safety: Adverse Events o Adverse Events related to study device or the index surgical procedure
To assess safety and characterize protocol defined adverse events and adverse device effects.
Time frame: Year 1,Year 3, Year 5, Year 7, and Year 10
Incidence of component revision
Determine the cumulative incidence of individual component revision at specified intervals out to 10 years follow-up.
Time frame: Year 1,Year 3, Year 5, Year 7, and Year 10
Started Oct 2023 (actual). Primary completion is estimated for Jun 2036, 152 months after the start.
Of 58 observational studies under Joint Diseases, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 153. This study's planned 152 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.